Veracyte
GenomeWeb Top 40 up 8 Percent in November, Outpacing Broader Market
The Dow Jones Industrial Average was up 6 percent last month, while the Nasdaq was up 4 percent and the Nasdaq Biotech Index was up 6 percent.
Veracyte Reports 25 Percent Q3 Revenue Growth, Raises Full-Year Guidance
The firm said that its Decipher and Afirma tests each benefited from expanded coverage and largely drove growth this quarter.
Veracyte Q2 Revenues up 32 Percent, Beat Analyst Expectations
The firm said the growth was due primarily to its portfolio of urology tests, which it brought on through its acquisition of Decipher Biosciences.
GenomeWeb Top 40 Down 5 Percent in June, Tracking Broader Market Decline
The Dow Jones Industrial Average was down 7 percent, and the Nasdaq was down 9 percent, though the Nasdaq Biotech Index was up 1 percent.
In Brief This Week: Sema4, Mirvie, Caris Life Sciences, Prenetics, 23andMe, More
News items for the week of May 2, 2022.
May 4, 2022
May 3, 2022
Veracyte Q1 Revenues Jump 85 Percent
Feb 28, 2022
Veracyte Revenues Almost Double in Q4
Nov 9, 2021
Veracyte Q3 Revenues Nearly Double
Oct 28, 2021
Jun 4, 2021
Jun 1, 2021
Veracyte to Acquire HalioDx for €260M
Feb 17, 2021